BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30503564)

  • 1. Molecular and pathologic characterization of AML with double Inv(3)(q21q26.2).
    Hodge JC; Bosler D; Rubinstein L; Sadri N; Shetty S
    Cancer Genet; 2019 Jan; 230():28-36. PubMed ID: 30503564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double Inv(3)(q21q26), a rare but recurrent chromosomal abnormality in myeloid hemopathies.
    De Braekeleer E; Douet-Guilbert N; Le Bris MJ; Ianotto JC; Berthou C; Gueganic N; Bovo C; Basinko A; Morel F; De Braekeleer M
    Anticancer Res; 2013 Feb; 33(2):639-42. PubMed ID: 23393360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.
    Gu J; Patel KP; Bai B; Liu CH; Tang G; Kantarjian HM; Tang Z; Abraham R; Luthra R; Medeiros LJ; Lin P; Lu X
    Mol Cytogenet; 2015; 8():68. PubMed ID: 26300976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
    Fonatsch C; Gudat H; Lengfelder E; Wandt H; Silling-Engelhardt G; Ludwig WD; Thiel E; Freund M; Bodenstein H; Schwieder G
    Leukemia; 1994 Aug; 8(8):1318-26. PubMed ID: 8057667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.
    Gong X; Yu T; Tang Q; Fu Y; Wu J; Zhu Y; Tu H; Ge H; Lu X; Gong D; Zhao X
    Int J Lab Hematol; 2019 Jun; 41(3):380-386. PubMed ID: 30793839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification.
    Sun J; Konoplev SN; Wang X; Cui W; Chen SS; Medeiros LJ; Lin P
    Mod Pathol; 2011 Mar; 24(3):384-9. PubMed ID: 21113141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
    Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
    Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
    Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
    Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
    Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies.
    Shi G; Weh HJ; Dührsen U; Zeller W; Hossfeld DK
    Cancer Genet Cytogenet; 1997 Jul; 96(1):58-63. PubMed ID: 9209472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia.
    Cui W; Sun J; Cotta CV; Medeiros LJ; Lin P
    Am J Clin Pathol; 2011 Aug; 136(2):282-8. PubMed ID: 21757602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia.
    Keung YK; Buss D; Powell BL; Pettenati M
    Cancer Genet Cytogenet; 2002 Jul; 136(1):78-81. PubMed ID: 12165457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26).
    Reiter E; Greinix H; Rabitsch W; Keil F; Schwarzinger I; Jaeger U; Lechner K; Worel N; Streubel B; Fonatsch C; Mitterbauer G; Kalhs P
    Ann Hematol; 2000 Jul; 79(7):374-7. PubMed ID: 10965785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.